A cobalt-loaded porphyrin complex, comprising the porphyrin (meso-tri(4-sulfonatophenyl) mono(4-carboxyphenyl)porphine (C.sub.1S.sub.3TPP)) with coordinated with cobalt, effectively neutralizes the biological activity of opioids.

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.

The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I:

T-L-X

wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.

Provided are vaccine compositions and methods for generation of immune response (including neutralizing antibodies) against SARS-CoV-2 virus. The vaccine compositions comprise a poly-histidine tagged receptor binding domain (RBD) of the SARS-CoV-2 virus incorporated into a liposome comprising cobalt-porphyrin-phospholipid conjugates, such that one or more histidines of the polyhistidine tag are coordinated to the cobalt of the cobalt-porphyrin and at least a portion of the RBD is exposed to the outside of the liposome.

Provided herein is a small molecule delivery system with illumination-induced small molecule release based on the binary combination of charged liposomes containing small molecules and oppositely charged conjugates of a peptide with a photosensitizer attached to one end of peptide chain, providing binding to liposomes and their permeabilization upon light illumination.

The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.

The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.

The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications.

The present invention provides a nanoparticle including at least one poly(vinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.

Compounds including a tetrapyrrolic or reduced tetrapyrrolic group/moiety and an epidermal growth factor receptor targeting group are disclosed. For example, a compound includes a tetrapyrrolic or reduced tetrapyrrolic group or moiety, a linker moiety, an epidermal growth factor receptor targeting group, and, optionally, a PET-active functional group. Uses of the compounds, for example, methods of treating a hyperproliferative tissue in an individual, and kits including one or more of the compounds are also provided.